Revumenib (SNDX-5613) is an orally bioavailable, potent, and selective Menin-MLL (Mixed Lineage Leukemia) inhibitor designed to target MLL-rearranged (MLL-r) and NPM1-mutant acute leukemias. In preclinical models, Revumenib has demonstrated low nanomolar potency with an IC₅₀ of approximately 8–20 nM for disruption of the Menin-MLL interaction, leading to downregulation of HOXA9 and MEIS1 expression, which are critical oncogenic drivers.
MedKoo Cat#: 127860
Name: Revumenib citrate
CAS#: 2761046-45-9 (citrate)
Chemical Formula: C38H57FN6O12S
Exact Mass: 840.3739
Molecular Weight: 840.96
Elemental Analysis: C, 54.27; H, 6.83; F, 2.26; N, 9.99; O, 22.83; S, 3.81
The following data is based on the product molecular weight 840.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
